Moneycontrol
Get App
SENSEX NIFTY
you are here:

Krebs Biochemicals & Industries Ltd.

BSE: 524518 | NSE: KREBSBIO |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE268B01013 | SECTOR: Pharmaceuticals

Success
Alert
Please select a Day.
Info

BSE Live

Feb 20, 16:00
104.00 7.20 (7.44%)
Volume
AVERAGE VOLUME
5-Day
1,459
10-Day
1,007
30-Day
689
281
  • Prev. Close

    96.80

  • Open Price

    94.20

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Feb 20, 15:55
98.35 2.60 (2.72%)
Volume
AVERAGE VOLUME
5-Day
5,474
10-Day
5,282
30-Day
3,396
3,779
  • Prev. Close

    95.75

  • Open Price

    98.95

  • Bid Price (Qty.)

    98.35 (35)

  • Offer Price (Qty.)

    0.00 (0)

Annual Report

For Year :
2004

Chairman's Speech

Mission Statement KREBS is committed to: * be the world-class, research-driven manufacturer of Biopharmaceuticals, Intermediaries, Agro industrial products to produce latest and Quality Products. * add Ethical Value to the Business Practices and conduct business with Integrity. * serve Customers, Shareholders and Society at large. * operate in a Safe and Echo - Friendly atmosphere. * conduct research constantly seeking innovations. Corporate Values The overall philosophy of the Company is to be an ideal and model Corporate Citizen and hence takes on itself to carry out its business by following good corporate practices like * Good Corporate Governance * Transparency and Honesty * Social Responsibility * Responsibility towards a) Employees b) Stakeholders c) Customers d) Suppliers and e) Society at large About the Company Krebs Biochemicals & Industries Limited (KBIL) was incorporated in the year 1991 as a Public Limited Company with the main objective of establishing commercially viable biotech processes with applications in Medicine, Agriculture and Industry. The company has pioneered in the fermentation technology over the last decade. KBIL went into public in the year March 1994 to part finance its fermentation technology project. KBIL has a strong shareholding community of over 10000 spread across all parts of the country. Presently the equity shares are listed on HSE, BSE and NSE with active trading on BSE. KBIL has manufacturing facilities at Ragadichelika, Nellore (Unit I) and at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District (Unit II). Products manufactured from Unit I.facility are Ephedrine, Pseudoephedrine and their salts, which are used for making formulations for respiratory ailments, viz., cough, cold etc. The facility at Unit II is being used to manufacture a basket of fermentation products viz., Lovastatin, Simvastatin, (all cholesterol reducing agents) and Vitamin-C and its salts (neutraceuticals), which has wider applications in Pharma, feeds, foods beverages etc. The company is focussing on the research and development of new bio molecules and genetically engineered products by synthetic and biological approaches. The R&D centres of KBIL situated at Unit I and ICICI Knowledge Park, Hyderabad are recognized by DSIR, New Delhi. The growth of KBIL is strengthened by its work force consisting of Doctorates, Post Graduates, Technocrats etc., KBIL has received ISO 9002 Certification for its Unit-I situated at Nellore from Yarsley International Certifications Services accredited by United Kingdom Accreditation Services (U.K.A.S.) in the year 2001. Unit I is also accredited with European Certificate of Suitability from European Directorate for the Quality of Medicines (EDQM). Further, Certificate of Suitability has been submitted to EDQM for Lovastatin and Simvastatin. The Unit I is a USFDA certified facility. Unit II is in the process of obtaining USFDA. The requirement of various criteria by USFDA involving appropriate designs, data collection, statistics and safety monitoring in concurrence with Good Manufacturing Practices and Good Laboratory Practices are followed by KBIL. KBILs past performance and success holds the strength for opening up new avenues for diversification/in addition to the existing line of bulk drugs. The company follows current Good Manufacturing Practices (cGMP) in addition to Good Business Practices. Under the diversification programme and as a part of seeking new opportunities, KBIL has set up stackable potato chips plant at Gaganpahad, Hyderabad. Further, KBIL has acquired The Nannapaneni Venkat Rao Co-operative Sugar Factory, Jampani under the privatisation process and successfully completed crushing operations for the season 2003-04. KBIL focuses on knowledge and expertise which will involve both experience and manpower skills necessary to organize suitable plant infrastructure at low cost for enabling the fermentation activities as an integral part of exploiting traditional microbial technology.